The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Mohindru Mani since 2018.
This trader's CIK number is 1664708.
At the time of last reporting, Mohindru Mani was the Chief Executive Officer of Cardiff Oncology, Inc.. (stock ticker symbol CRDF).
Also see all insider trading activities at Cardiff Oncology, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | CARA | 0 | $0 | 65,223 | $1,433,414 | 53,472 | $751,815 |
| 2018 | CARA | 0 | $0 | 32,084 | $620,664 | 32,084 | $451,100 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | CRDF | 24,703 | $29,890 | 0 | $0 | 0 | $0 |
1. Cara Therapeutics, Inc. (CARA)
2. Cardiff Oncology, Inc. (CRDF)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-12-04 | CARA | Sale | 4,755 | 17.05 | 81,072 |
| 2019-07-15 | CARA | Option Ex | 37,431 | 14.06 | 526,279 |
| 2019-07-15 | CARA | Sale | 37,431 | 25.00 | 935,775 |
| 2019-05-29 | CARA | Sale | 2,496 | 21.39 | 53,389 |
| 2019-03-13 | CARA | Sale | 16,041 | 19.12 | 306,703 |
| 2019-03-13 | CARA | Option Ex | 16,041 | 14.06 | 225,536 |
| 2018-12-28 | CARA | Sale | 4,500 | 12.55 | 56,475 |
| 2018-11-15 | CARA | Option Ex | 16,042 | 14.06 | 225,550 |
| 2018-11-15 | CARA | Sale | 16,042 | 18.50 | 296,777 |
| 2018-10-17 | CARA | Option Ex | 16,042 | 14.06 | 225,550 |
| 2018-10-17 | CARA | Sale | 16,042 | 20.19 | 323,887 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-18 | CRDF | Buy | 24,703 | 1.21 | 29,890 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mohindru Mani (Chief Executive Officer of Cardiff Oncology, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.